Side-by-side financials for CHRS and BNTX. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CHRS | BNTX |
|---|---|---|
| Market cap | - | $22.90 B |
| US-listed rank | - | #572 |
| Revenue (latest FY) | $42.17M | - |
| Net income (latest FY) | $168.02M | - |
| Net margin | 398.4% | - |
| SEC filings | 898 | 548 |
Full pages: Coherus BioSciences, Inc. and BioNTech SE, or browse the full rankings.